{"id":3162,"date":"2021-12-01T22:32:11","date_gmt":"2021-12-01T22:32:11","guid":{"rendered":"https:\/\/bxta.com\/?p=3162"},"modified":"2021-12-09T14:10:47","modified_gmt":"2021-12-09T14:10:47","slug":"bxta-newsletter-november-2021","status":"publish","type":"post","link":"https:\/\/bxta.com\/uk\/bxta-newsletter-november-2021\/","title":{"rendered":"BXTA Newsletter November 2021"},"content":{"rendered":"\n
\n
\"Bxta<\/figure>\n\n\n\n
<\/div>\n\n\n\n

Jonah (Urology Nurse Award) <\/h2>\n\n\n\n
\"\"<\/figure><\/div>\n\n\n\n

Earlier this year at the annual British Journal of Nursing (BJN) Awards, Jonah Rusere, Prostate Clinical Nurse Specialist at Guy\u2019s and St Thomas\u2019 NHS Foundation Trust, and Advanced Nurse Practitioner for South East London Accountable Cancer Network, won the \u2018Urology Nurse of the Year\u2019 award.<\/p>\n\n\n\n

The Urology Nurse of the Year Award, supported by the British Association of Urological Nurses (BAUN), is for nurses who have achieved excellence or shown a flair for innovation to improve patient care in urology.<\/p>\n\n\n\n

The BJN Awards recognised Jonah for \u201calmost single-handedly transforming prostate biopsy practice across the UK by rolling out an initiative to introduce a biopsy process using local rather than a general anaesthetic, providing a much safer and more effective diagnostic procedure\u201d.<\/p>\n\n\n\n

After receiving the award, Jonah said: \u201cIt is a privilege to receive the award. I want to thank the team at Guy\u2019s Hospital and those at the South East London Accountable Cancer Network for acknowledging the work we\u2019ve done over the last three years with LATP biopsies. I\u2019m grateful and thankful for the BJN community to honour me with Urology Nurse of the Year.\u201d<\/p>\n\n\n\n

Jonah, as well as Rick Popert, Consultant Urologist, Guy\u2019s and St Thomas\u2019, have continued to drive the TRexit initiative forward, helping hospitals to phase out TRUS biopsies and replace them with transperineal biopsies under local anaesthetic (LA TP). This transition is supported through devices such as the PrecisionPoint™ transperineal access system that facilitate local anaesthetic TP biopsy through a freehand approach. Now, over 80% of TP biopsies at Guy\u2019s are performed solely under local anaesthetic, with over half performed in the outpatient setting. MSAC Campaign: The Medical Services Advisory Committee (MSAC) is an independent non-statutory committee established by the Australian Government Minister for Health in 1998. The MSAC appraises new medical services proposed for public funding and provides advice to Government on whether a new medical service should be publicly funded, using the best available evidence.<\/p>\n\n\n\n

However, the committee has twice rejected the application to extend the LDR brachytherapy indication to include LDR boost with ERBT for higher-risk prostate cancer, despite evidence proving that LDR-Boost has the equivalent safety and efficacy data to treatments currently listed on medicare. In turn, this, therefore, means that Australian men are being denied access to a treatment that is standard of care elsewhere in the world, unless they are able to self-fund the full cost of treatment. BXTA, VIVA! Communications and Insight Strategy are working in collaboration on a public and government relations campaign to lobby the Australian Health Minister to request MSAC to reconsider their original application. Nicola Leavold,<\/p>\n\n\n\n

<\/div>\n\n\n\n
\n

MSAC Campaign:<\/h2>\n\n\n\n

The Medical Services Advisory Committee (MSAC) is an independent non-statutory committee established by the Australian Government Minister for Health in 1998. The MSAC appraises new medical services proposed for public funding and provides advice to Government on whether a new medical service should be publicly funded, using the best available evidence.<\/p>\n\n\n\n

However, the committee has twice rejected the application to extend the LDR brachytherapy indication to include LDR boost with ERBT for higher-risk prostate cancer, despite evidence proving that LDR-Boost has the equivalent safety and efficacy data to treatments currently listed on medicare.<\/p>\n\n\n\n

In turn, this, therefore, means that Australian men are being denied access to a treatment that is standard of care elsewhere in the world, unless they are able to self-fund the full cost of treatment.<\/p>\n\n\n\n

BXTA, VIVA! Communications and Insight Strategy are working in collaboration on a public and government relations campaign to lobby the Australian Health Minister to request MSAC to reconsider their original application.<\/p>\n\n\n\n

Nicola Leavold, BXTA\u2019s Commercial Director in Australasia was invited to speak at a recent parliamentary enquiry into the way medical devices are approved within Australia. They echoed the industry\u2019s frustration with the lack of transparency with the MSAC process, and are requesting a greater opportunity for dialogue between clinical experts, industry and the MSAC process. You can support this appeal by writing to your local MP, using this Pro-forma letter here: <\/span> backingbrachy.com\/au<\/a><\/span><\/p>\n<\/div><\/div><\/div>\n\n\n\n

<\/div>\n\n\n\n
<\/div><\/div><\/div>\n\n\n\n

New Mission Statement And Vision<\/h1>\n\n\n\n

BXTA has extended its global presence to support healthcare professionals improve outcomes and quality of life for prostate cancer patients. Since its foundation in 2012, BXTA has, in partnership with prostate cancer treatment centres and specialists, developed innovative solutions for the treatment of prostate cancer, including 4D low-dose-rate brachytherapy (4D LDR-B) as well as championed a pioneering new technique for prostate cancer biopsy, the PrecisionPoint™ Transperineal Access System from Perineologic.<\/p>\n\n\n\n

PrecisionPoint™ is the biopsy technique behind the TRexit initiative, which aims to eradicate transrectal (TRUS) biopsies from the prostate cancer pathway in the NHS by the end of 2021, in favour of the local anaesthetic transperineal (LA TP) biopsy. This is a move that is also endorsed by the European Urology Association in their 2021 guidelines. <\/p>\n\n\n\n

Since gaining its CE Mark in 2018, almost 87% of hospitals across the UK that are performing TP biopsies today are using PrecisionPoint™ (HES data 2020\/21).<\/p>\n\n\n\n

Between 2020\/21, 30,116 biopsies took place (compared to 58,986 in 2019\/20 as a result of COVID-19), with 66% of these being carried out via the transperineal route. Compared to data from 2018\/2019, over 66% of prostate biopsies were transrectal, demonstrating the impact of TRexit and the change in attitude that has taken place.<\/p>\n\n\n\n

This has been supported by a national training programme, developed and delivered by BXTA in collaboration with Mr Rick Popert, Guy\u2019s & St. Thomas\u2019 NHS Trust, aimed at increasing the number of nurses skilled in undertaking LA TP biopsies. This has provided opportunities for Clinical Nurse Specialists (CNS) to add value to the prostate cancer pathway. Discussing his prostate cancer experience, Russell applauds the process from diagnosis to the operation:<\/p>\n\n\n\n

The evidence base for PrecisionPoint™ is underpinned by a significant number of clinical papers, which include data on clinical outcomes such as reduced sepsis rates and improved cancer detection; as well as operational and financial data to support the move from TRUS to LA TP with PrecisionPoint, over alternative methods for LA TP.<\/p>\n\n\n\n

Saheed Rashid, Managing Director, BXTA, comments: \u201cWe are immensely proud of the success of the TRexit initiative to date in the UK and aim to replicate that elsewhere in the world to offer patients better, safer biopsies, as well as continue to advocate the benefits of low-dose-rate brachytherapy as an alternative to more invasive treatment options for prostate. cancer.\u201d<\/p>\n\n\n\n

\"\"<\/figure><\/div>\n\n\n\n

Values:<\/span><\/strong><\/p>\n\n\n\n